NasdaqGS - Delayed Quote
USD
Moderna, Inc. (MRNA)
45.37
-0.57
(-1.24%)
At close: May 1 at 4:00:01 PM EDT
45.04
-0.33
(-0.73%)
After hours: May 1 at 7:59:24 PM EDT
Trade Moderna on Coinbase
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreLoading chart for MRNA
- Previous Close
45.94 - Open
46.25 - Bid 42.48 x 100
- Ask 47.29 x 100
- Day's Range
43.68 - 48.40 - 52 Week Range
22.28 - 59.55 - Volume
10,213,373 - Avg. Volume
8,019,480 - Market Cap (intraday)
17.993B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-7.26 - Earnings Date (est.) Jul 31, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
42.58
Recent News: MRNA
View More
Performance Overview: MRNA
Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
MRNA
53.85%
S&P 500 (^GSPC)
5.62%
1-Year Return
MRNA
67.85%
S&P 500 (^GSPC)
29.01%
3-Year Return
MRNA
65.99%
S&P 500 (^GSPC)
73.47%
5-Year Return
MRNA
74.63%
S&P 500 (^GSPC)
72.92%
Earnings Trends: MRNA
View MoreAnalyst Insights: MRNA
View MoreStatistics: MRNA
View MoreValuation Measures
As of 5/1/2026
-
Market Cap
17.99B
-
Enterprise Value
13.50B
-
Trailing P/E
--
-
Forward P/E
--
-
PEG Ratio (5yr expected)
--
-
Price/Sales (ttm)
9.18
-
Price/Book (mrq)
2.08
-
Enterprise Value/Revenue
7.02
-
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
-
Profit Margin
-143.55%
-
Return on Assets (ttm)
-17.63%
-
Return on Equity (ttm)
-36.56%
-
Revenue (ttm)
2.22B
-
Net Income Avi to Common (ttm)
-3.19B
-
Diluted EPS (ttm)
-7.26
Balance Sheet and Cash Flow
-
Total Cash (mrq)
5.21B
-
Total Debt/Equity (mrq)
16.85%
-
Levered Free Cash Flow (ttm)
-497.75M
Compare To: MRNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: MRNA
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports: MRNA
View More-
Moderna Earnings: All Eyes on Upcoming Data for Oncology Therapy Intismeran
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
RatingPrice Target -
Moderna: Litigation Settlement Removes Royalty Risk; We Still Estimate Breakeven by 2029
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
RatingPrice Target -
Argus Quick Note: Weekly Stock List for 04/27/2026: Shooting Stars and Falling Angels in 1Q26
To date, 2026 has been a volatile year for stocks. The major indices started the year by moving higher, but that changed with the onset of the war with Iran on February 28. As oil prices began to climb rapidly, stock prices fell inversely. The Mag7 were out, but now seem to be back in (or at least most of them). AI was in and remains in. Of note, this is President Trump's second year in office, and typically, the second year of a presidency is weak for stocks. Meanwhile, inflation is slowly-and-steadily inching higher again and interest rates haven't budged since the Federal Reserve's last rate cut in December. In 1Q26, the S&P 500 fell 4.3%. In the Argus universe of more than 500 public companies, the average share-price decline was 0.3%, and the median decline was 2%. The following stocks are the top-10 and the bottom-five performers from the Argus universe during 1Q. Among the winners, we note that five are from Information Technology, two from Materials, two from Energy, and one from Healthcare. Why do we study past performance? We want to know which stocks weathered the storms that were presented, the mix of sector performance, and the emergence of new names in the performance derby.
-
Looking for a more favorable entry point
Moderna Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious and cardiovascular diseases, rare diseases, immunological conditions, and cancer. The company has approximately 4,700 employees.
RatingPrice Target
